Safety and Efficacy of Lenabasum, a Cannabinoid Receptor Type 2 Agonist, in Patients with Dermatomyositis with Refractory Skin Disease: A Randomized Clinical Trial
Victoria P. Werth, Emily Z. Hejazi, S.M. Peña, Jessica S. Haber, Majid Zeidi, Nithin Reddy, Joyce Okawa, Rui Feng, Muhammad M. Bashir, Kirubel Gebre, Arvin Jadoo, Josef Symon S. Concha, Nancy Dgetluck, S. Constantine, Barbara White
Topics & Concepts
MedicineDermatomyositisInternal medicinePlaceboAdverse effectHydroxychloroquineRandomized controlled trialPopulationSeverity of illnessGastroenterologyDermatologyDiseasePathologyCoronavirus disease 2019 (COVID-19)Alternative medicineEnvironmental healthInfectious disease (medical specialty)Cannabis and Cannabinoid ResearchBipolar Disorder and TreatmentGenetic Neurodegenerative Diseases